Used in targeted cancer therapy, particularly for urothelial carcinoma. Binds specifically to Nectin-4, a cell adhesion molecule overexpressed in several solid tumors. This binding enables selective delivery of cytotoxic agents when conjugated to drugs, as seen in antibody-drug conjugates like enfortumab vedotin. Facilitates tumor cell killing while minimizing damage to healthy tissues. Also serves as a reference standard in development and testing of biosimilars and diagnostic assays. Supports research in oncology for understanding tumor biology and evaluating new therapeutic formats.